Skip to main content

Table 2 Reversal of MCT-Induced PAH by VIP, Bosentan, or Their Combination

From: VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

Measurements

Control, untreated

MCT +

P value (post hoc)

  

0

VIP

Bosentan

VIP + Bosentan

*

†

**

RV systolic pressure (mm Hg)

24.3 ± 2.4

61.4 ± 4.8

33 ± 0.5

39 ± 1.2

26.0 ± 1.2

< 0.05

< 0.05

< 0.05

Arteriolar medial/luminal area

0.76 ± 0.07

3.9 ± 0.51

1.68 ± 0.19

1.76 ± 0.19

0.79 ± 0.05

< 0.05

< 0.05

< 0.05

RV/(LV+septum) weight ratio

0.26 ± 0.01

0.56 ± 0.03

0.51 ± 0.03

0.47 ± 0.07

0.34 ± 0.02

NS

NS

< 0.05

Lung inflammation (0-4)

0.20 ± 0.17

3.0 ± 0.26

0.3 ± 0.21

1.2 ± 0.28

0.3 ± 0.33

< 0.05

< 0.05

< 0.05

  1. Therapy with either drug, or both together, was begun 3 weeks following MCT, i.e., after PH had fully developed. ANOVA: p < 0.0001
  2. * MCT + VIP vs. MCT; † MCT + Bosentan vs. MCT; ** MCT + VIP + bosentan vs. MCT